RESEARCH TRIANGLE PARK, N.C.  – December 4, 2014 – Quintiles today announced that the company was awarded “Best Contract Research Organization” at the annual SCRIP Awards for the third year in-a-row. This is the company’s fourth award received in this category in the last five years. The SCRIP Awards acknowledge excellence in the biopharmaceutical industry, based on judging by an independent panel of 12 life sciences experts.

“Our judges felt Quintiles was a worthy winner of the Best Contract Research Organization trophy for the third year in a row,” said Mike Ward, global director of content for IBI Pharma News & Datamonitor Healthcare.  “In the qualifying year, Quintiles once again demonstrated a series of performance milestones in its quest to improve its customers' probability of success.  Among its many accomplishments, Quintiles signed a series of transformational partnerships and launched innovative technologies to improve trial execution.  Despite plenty of competition, Quintiles remains the CRO to beat.”

Commenting on the award, Paula Brown Stafford, president of Clinical Development at Quintiles said, “To be recognized for the third straight year by SCRIP is a tremendous accomplishment.  It demonstrates the true impact that Quintiles has on improving our customers’ probability of success and on the broader biopharmaceutical industry.  We are honored to receive this award, and I would like to dedicate it to our employees around the world who made all of our tremendous accomplishments this past year possible.”

The tenth annual SCRIP awards ceremony was held in London and was attended by industry leaders from around the world.

About Quintiles

Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services.  With a network of more than 32,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit


Mari Mansfield, Media Relations ( 
+ 1.919.998.2639 (office) +1.919.259.3298 (mobile)
Karl Deonanan, Investor Relations (